CommercialCoverageMedium impact
08.00.64i, Natalizumab (Tysabri®) and Related Biosimilars
Independence Blue Cross·Neurology, Gastroenterology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated their policy for Natalizumab (Tysabri®) and related biosimilars under their commercial plans. This pharmacy policy became effective October 1, 2025, though specific details about coverage changes, prior authorization requirements, or billing modifications are not provided in the summary.
Action Required
By October 1, 2025: Billing team should review the complete policy at the provided URL to identify specific changes to Natalizumab billing requirements, prior authorization processes, or coverage criteria for commercial Independence Blue Cross plans. Update billing protocols accordingly based on the detailed policy content.